Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

EMEA Marketing Recommendation May Give European Alli A Boost

This article was originally published in The Tan Sheet

Executive Summary

The European Medicines Agency's support for a marketing authorization for orlistat in Europe signals a key step in GlaxoSmithKline's plan to launch a nonprescription version of the weight-loss drug in that part of the world, the company says

You may also be interested in...



EU Shifts To Centralized OTC Process At Member States’ Expense – GSK Exec

Europe's development of a centralized process for approving nonprescription pharmaceuticals is sapping the resources of the regulatory agencies of European Union member states, a GlaxoSmithKline regulatory executive says

EU Shifts To Centralized OTC Process At Member States’ Expense – GSK Exec

Europe's development of a centralized process for approving nonprescription pharmaceuticals is sapping the resources of the regulatory agencies of European Union member states, a GlaxoSmithKline regulatory executive says

EU Shifts To Centralized OTC Process At Member States’ Expense – GSK Exec

Europe's development of a centralized process for approving nonprescription pharmaceuticals is sapping the resources of the regulatory agencies of European Union member states, a GlaxoSmithKline regulatory executive says

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS100588

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel